Chronic phase chronic myeloid leukemia: Response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response

Journal of Association of Physicians of India

Volumn 55, Issue FEB., 2007, Pages 103-107

  Usman, M ^a   Syed, N N ^a   Kakepoto, G N ^a   Adil, S N ^a   Khurshid, M ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CHILD; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE TARGETING; GENE TRANSLOCATION; GENETICS; HUMAN; MALE; MIDDLE AGED; ONCOLOGY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; CHILD; CYTOGENETIC ANALYSIS; CYTOGENETICS; FEMALE; FUSION PROTEINS, BCR-ABL; GENE TARGETING; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM STAGING; PIPERAZINES; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TIME FACTORS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 34247466431     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bumm T, Muller C, Kathrin Al-Ali H, et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003;101: 1941-9.
2. Cortes J, Dwyer MEO. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin N Am 2004;18:671-84.
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
4. Berger U, Maywald O, Pfirrmann M, et al. Gender aspects in chronic myeloid leukemia: long term results of randomized studies. Leuk 2005;19:984-9.
5. Wang L, Pearson K, Ferguson JE, et al. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukemia. Br J Hematol 2003;120:990-9.
6. Usman M, Kakepoto GN, Adil SN, et al. Hematologic and cytogenetic findings in eleven chronic myelogenous leukemia patients treated with imatinib mesylate at a tertiary care hospital. J Pak Med Assoc 2004;54:17-20.
7. Vardiman JW, Pierre R, Thiele J. Chronic myelogenous leukemia. In Jaffe ES, Harris NL, Stein H, Vardiman JW. World health organization classification of tumors. Pathology and genetics tumors of haemopoietic and lymphoid tissues. IARC Press 2001:20-26.
8. Kantarjian HM, O'Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase. Cancer 2003;98:2636-42.
9. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101:3794-3800.
10. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: result of phase 2 study. Blood 2002;99:1928-1937.
11. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984;63:789-99.
12. Cortes J. Natural history and staging of chronic myeloid leukemia. Hematol Oncol Clin N Am 2004;18:569-84.
13. National clinical registry programme: consolidation report of cancer registries 1990-96.
14. Deshmukh C, Saikia T, Bakshi A, et al. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study. J Assoc Physicians India 2005;53:291-5.
15. Kantarjian HM, Sawyer C, Hochhaus A, et al. Hematologic and cytogenetic response to imatinib mesylate in chronic myelogenous leukemia. New Engl J Med 2002;346:645-52.
16. Crossman LC, O'Brien SG. Imatinib therapy in chronic myeloid leukemia. Hematol Oncol Clin N Am 2004;18:605-17.
17. Rosti G, Trabacchi E, Bassi S, et al. Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica 2003;88:256-9.
18. Cervantes F, Hernandez-Boluda JC, Steegmann JL, et al. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. Haematologica 2003;88:1117-22.
19. Baccarrani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European leukemia net. Blood 2006;108:1809-22.
20. Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL leukemia treated with imatinib in a single center. A 4.5 year follow-up. Cancer 2005;103:1659-70.